Despite great progress in curing childhood acute lymphoblastic leukemia (ALL), survival after relapse remains poor. We analyzed survival after relapse among 9585 pediatric patients enrolled on Children's Oncology Group clinical trials between 1988 and 2002. A total of 1961 patients (20.5%) experienced relapse at any site. The primary end point was survival. Patients were subcategorized by the site of relapse and timing of relapse from initial diagnosis. Time to relapse remains the strongest predictor of survival. Patients experiencing early relapse less than 18 months from initial diagnosis had a particularly poor outcome with a 5-year survival estimate of 21.0±1.8%. Standard risk patients who relapsed had improved survival compared with their higher risk counterparts; differences in survival for the two risk groups was most pronounced for patients relapsing after 18 months. Adjusting for both time and relapse site, multivariate analysis showed that age (10 þ years) and the presence of central nervous system disease at diagnosis, male gender, and T-cell disease were significant predictors of inferior post-relapse survival. It can be noted that there was no difference in survival rates for relapsed patients in earlier vs later era trials. New therapeutic strategies are urgently needed for children with relapsed ALL and efforts should focus on discovering the biological pathways that mediate drug resistance.
Introduction
Overall cure rates for newly diagnosed children with acute lymphoblastic leukemia (ALL) approach 80% 1,2 with currently available therapies. However, even with risk-stratified and more intensive frontline therapy, 20-25% of children with ALL still relapse, accounting for a large number of pediatric cancer patients. [3] [4] [5] [6] The treatment of patients with relapsed ALL remains unsatisfactory, with suboptimal re-induction remission rates and poor long-term overall survival rates ranging from 15 to 50%. [7] [8] [9] [10] [11] Previous studies have demonstrated that successful treatment of relapsed ALL has been closely correlated with the length of the first clinical remission (CR1) and the site of relapse. 7, 12 Survival after a bone marrow (BM) relapse is worse than after an extramedullary event, and the worst outcomes are significantly associated with earlier relapse while on therapy. Most papers define early relapses occurring in the first 18 months from diagnosis, intermediate relapses occurring between 18 and 36 months from diagnosis and late relapses occurring after 36 months. Survival for patients experiencing early BM relapse range from 0 to 15%, 13, 14 whereas those with intermediate medullary relapses have survival rates from 10 to 40%. 12, 14 For patients with late BM relapses, survival rates range from 14 to 50%. 15 Relapses involving sites other than BM have better prognoses: the survival rates for central nervous system (CNS) relapses approach 51% 16 and those for isolated testicular relapses range from 53 to 84%. 17, 18 Treatment for relapsed ALL primarily involves many of the same traditional chemotherapy agents initially used as well as stem cell transplantation. The benefits of stem cell transplantation vs aggressive chemotherapy for different patient groups remain unclear, but the overall poor outcomes and long-term sequelae from both strategies render neither of them ideal treatments. 15, [19] [20] [21] [22] Efforts must focus on improving our understanding of the biological factors contributing to relapse and identifying new agents that will increase the chances of a sustained second remission. We conducted this retrospective study to determine whether patterns of survival after relapse have changed with more intensive frontline therapy on contemporary clinical trials. We describe the diagnostic characteristics and outcomes after relapse for a large number of patients relapsing on the generation of Children's Oncology Group trials opened from 1988 to 2002, to determine whether newer treatment strategies have altered the survival of ALL after relapse.
Materials and methods

Clinical trials
Data used in this study were collected as part of Children's Cancer Group (CCG) protocols that enrolled patients between December 1988 and 2002. All patients and guardians participated in these trials with informed consent. A total of 9585 children with newly diagnosed B-precursor or T-cell ALL were enrolled in CCG-1881, CCG-1882, CCG-1883, CCG-1891, CCG-1901, CCG-1922, CCG-1952, CCG-1953, CCG-1961 and CCG-1962 trials. For all protocols, any patient with a diagnosis of mature B-cell leukemia or acute myeloid leukemia was ineligible for enrollment. A description of these trials, accrual dates, total enrollment and overall 5-year event-free survival (EFS) rates are listed in Table 1.  Table 2 compares the clinical characteristics of the patients who relapsed with those who remained in CR1. The primary end point was overall survival after first relapse (information on subsequent adverse events was not collected). After relapse on initial trials, the only data collected were those pertaining to survival. Thus, we cannot comment on EFS or analyze outcome based on the treatment administered after relapse.
Risk stratification
The risk stratification algorithms used for patient eligibility are summarized below.
For studies open prior to 1995: low risk: 2-9 years of age at diagnosis with an initial white blood cells (WBC) count less than 10 000/ml. 23 Intermediate risk: ages 2-10 years with a WBC count of 10 000-50 000/ml, no bulky extramedullary disease, or in boys with platelet counts less than 100 000/ml, a WBC less than 10 000/ml, or in children 1 to 2 years of age, a WBC less than 50 000/ml. 24 High risk (HR): 1-9 years old with WBC count of X50 000/ml or X10 years old irrespective of WBC, excluding patients with lymphomatous features. 21 For studies including CCG-1922, CCG-1952, CCG-1953, CCG-1961 and CCG-1962, risk stratification followed the National Cancer Institute (NCI)-Rome risk criteria: 25 standard risk (SR): age 1 through 9.99 years and diagnostic WBC count of o50 000/ml. HR: all others up to the age of 21 years.
Immunophenotypic classification was determined as follows: B-lineage ALL: 430% CD19 positivity, 430% CD10 or CD 20 positivity; T-lineage ALL: 430% CD7 positivity. Diagnostic karyotyping of leukemic cells was performed by local institutions prior to the initiation of therapy; however, results were not uniformly submitted for central review.
Statistical analyses
Differences in proportions of clinical characteristics at diagnosis between patients who relapsed and those who did not were assessed using w 2 tests. Outcome analyses used life table methods and associated statistics. The primary end point examined was overall survival post relapse. Life table estimates were calculated by the Kaplan-Meier (KM) procedure, 26 and the standard error (s.e.) of the life table estimate was obtained by the method of Peto. 27 The log rank test was used to compare outcome between groups. Cox proportional hazards regression models were used to evaluate the significance of differences in survival between groups. When the proportional hazards assumption seemed unsatisfactory for a predictor in the Cox model, the effects of other variables were adjusted by stratifying the predictor in question. Five-year post-relapse survival rates are presented here for various subgroups.
Results
Overview of clinical trials
Between 1988 and 2002, a total of 9585 patients with de novo ALL were enrolled on CCG clinical trials and 1961 children experienced a relapse at any site. The distribution of relapse sites was as follows: isolated marrow 57.3%, concurrent marrow 13.5%, isolated CNS 20.9%, isolated testicular 5.3%, other extramedullary ± CNS 3.1%. Overall enrollment and 5-year EFS rates by protocol are given in Table 1 . EFS rates ranged from 37.6 to 82.3%. Among all relapsed patients, the median followup time from initial diagnosis was 51.6 months. After experiencing relapse, the median follow-up time was 15.7 months. Duration of CR1 for patients who relapsed varied accordingly with NCI risk group at diagnosis, with shorter duration of remission coinciding largely with higher risk features at diagnosis (Tables 1 and 2 A comparison of diagnostic features of patients who relapsed with those who did not is given in Table 2 . The relapsed cohort had a higher percent of patients who fell in the age range o1 or X10 years (P ¼ 0.0001). Similarly, there was a higher proportion of males in the relapsed group (P ¼ 0.0002). Nearly 20% of the patients who relapsed presented with an initial WBC count 4100 000/ml. In comparison with Caucasians, more children of African American or Hispanic ethnicity experienced relapse (P ¼ 0.0001). There was no significant difference in the distribution of immunophenotype (B-precursor or T-cell) between the patients who relapsed vs those who did not. It was not possible to determine the distribution of other diagnostic variables such as cytogenetics, because of insufficient data.
Measurements of early response to therapy were captured by day 7 and/or day 14 marrow morphology status, although not all studies uniformly captured both time points. Of the 4064 patients achieving an M1 marrow by day 7, 662 (16.2%) relapsed, whereas 537 of 2547 (21.1%) patients with a slower response to initial therapy (for example, achieving an M1 marrow by day 14) experienced relapse (P ¼ 0.0001). Of the 630 patients who were M2 or M3 on day 14, 263 (41.7%) relapsed (P ¼ 0.0001). Taken together, these data support the previous observation that slow early response is associated with inferior EFS.
Features associated with survival after relapse
Relapse events were defined by time from initial diagnosis (early: o18 months; intermediate: 18-36 months; late: X36 months) and site (isolated marrow, concurrent marrow, isolated CNS, isolated testicular and other extramedullary ± CNS). Table 3 gives 5-year survival rates after relapse by site and timing of relapse.
Overall post-relapse survival rates were higher (Po0.0001) for patients with isolated CNS relapse (58.7 ± 3.2%) than for patients with either isolated (24.1 ± 2.1%) or concurrent BM (39.4±5.0%) relapses. Survival rates after early relapse were higher for patients with isolated CNS relapse than for patients with either isolated or combined BM relapse (5-year survival ratesFisolated CNS: 43.5 ± 4.5% vs isolated marrow: 11.5±1.9% vs concurrent marrow: 11.6±4.9%, Po0.0001). This was also true for intermediate and late relapsing patients. Survival rates were also significantly higher for patients with concurrent marrow relapses compared with those with isolated marrow relapsesFoverall (Po0.0001), intermediate (P ¼ 0.002), late (P ¼ 0.02). Survival rates were identical for the Survival after relapse from childhood ALL K Nguyen et al (Figure 2) .
In general, frontline therapy for ALL has intensified over time to improve EFS. It has been speculated that patients treated intensively at initial diagnosis might be more refractory to salvage therapy. To examine this further, we assessed survival after relapse for patients with any marrow relapse stratified by treatment era (early vs late trials). We defined early treatment protocols to include CCG-1881, CCG-1882, CCG-1883, CCG-1891, CCG-1901 and CCG-1922, and later era trials to include Abbreviations: CCG, Children's Cancer Group; CNS, central nervous system; EFS, event-free survival; NA, not applicable; WBC, white blood cells. *P-valueo0.001 (significant difference in clinical characteristic between relapsed and did not relapse). **P-valueo0.001 (Significant differences in EFS between categories for the clinical characteristic).
Survival after relapse from childhood ALL K Nguyen et al Univariate analyses (n ¼ 1961) were conducted to study the association of presenting clinical and laboratory features at initial diagnosis, time to relapse and the site of relapse with survival post relapse (Table 4 ). Significant associations were found with site and timing of relapse, age at diagnosis, WBC at diagnosis, lineage (B vs T), CNS status at diagnosis, race and NCI risk; exceptions were trial era and sex. Multivariate analyses stratified by timing of relapse and the site of relapse were conducted on the subset of patients (n ¼ 1391) with complete data for all the variables (Table 5) . Infants o1 year of age at diagnosis were excluded from the multivariate analyses, as they cannot be classified by NCI risk group. Age at diagnosis, CNS disease, sex, lineage and NCI risk group were significant predictors of survival post relapse. Trial era, WBC at diagnosis and race were not significant in predicting survival in the multivariate analysis. Multivariate analyses stratified for time to relapse, the site of relapse and age at diagnosis resulted in the same significant predictors as before. Trial era, WBC at diagnosis and race were not significant factors.
Discussion
Despite improved treatments and increasing dose intensity in primary therapy for newly diagnosed patients with ALL, patients Figure 2 Kaplan-Meier estimates of survival after relapse for patients stratified by NCI risk group at diagnosis and timing of relapse. There were significant differences in outcome for those SR vs HR patients experiencing either an early (33.1±3.6 vs 14.9±2.1%, Po0.0001), intermediate (52.2±3.7 vs 22.0±3.9%, Po0.0001) or late relapse (59.6 ± 4.6 vs 39.5 ± 7.2%, Po0.0001). 28 This study analyzed survival after relapse for almost 10 000 children diagnosed with ALL between 1988 and 2002, of whom 1961 (20.5%) relapsed. Not surprisingly, survival after relapse remains most dismal for those patients experiencing a BM relapse within 18 months of initial diagnosis. High-risk patients have higher mortality than their SR counterparts irrespective of the time to relapse. Male sex, age o1 year or X10 years at diagnosis, T-cell lineage and CNS disease at diagnosis persist as predictors of increased risk of death after relapse, even when controlled for by site and time to relapse. New studies clearly need to address how to effectively treat relapsed patients and maintain durable remissions.
Our analysis failed to demonstrate any substantial differences in survival after relapse for patients treated on a recent generation Children's Oncology Group-sponsored ALL trial vs 762 children enrolled on earlier CCG trials between 1983 and 1989. 12 Although we have witnessed improved EFS for newly diagnosed patients by exposing them to more intense treatment and potentially greater morbidity, we remain unable to salvage the majority of children who fail initial therapy. The data presented here support our ongoing efforts to optimize risk stratification to identify patients at diagnosis who require more intense or novel therapies to achieve cure. In particular, this study provides compelling data that NCI HR patients do exceptionally poorly after relapsing at any time, thus warranting new approaches to optimizing therapy at diagnosis.
It is curious to note that although no differences in survival after relapse were noted for patients relapsing off older era trials vs more contemporary trials, patients who are SR at diagnosis have improved survival compared with their HR counterparts irrespective of time to relapse. Certainly, the distribution of patients experiencing early, intermediate and late relapses were highly skewed toward NCI HR patients in the former group and NCI SR in the latter group (Figure 2b) . Although NCI SR patients receive less intense therapy, these data suggest that intrinsic differences in the biology of the leukemic blasts are correlated with different mechanisms and timing of relapse. For instance, NCI SR patients have a much higher incidence of favorable genotypes like hyperdiploidy and TEL-AML1, whereas older patients are more likely to be BCR-ABL-positive.
Previously, Gaynon et al. 12 reported survival after ALL relapse of children enrolled on Children's Cancer Group clinical trials between 1983 and 1989. In that analysis, the strongest predictor of prolonged survival after relapse was an initial time to first relapse of X36 months. Importantly, patients with an isolated BM relapse who failed initial therapy less than 18 months from diagnosis had a 4.5-fold higher relative risk for death than those relapsing after 36 months. In our updated analysis and a review of the literature, the two most significant predictors of survival after relapse remain the sameFsite and time. This observation continues to raise essential questions about the biology of relapsed ALL, which will need to be addressed if we are going to be remotely successful in curing these patients.
Indeed, recent analyses have indicated that there is a unique and distinct pattern of gene expression in pairs of relapsed samples from patients who relapse early from those who relapse later. 29 It has been shown that paired samples from patients experiencing early relapse are more similar in expression patterns than paired samples from those relapsing later. Early relapse is also characterized by increased expression of genes involved in proliferation and survival. 29 It is likely that resistant leukemia cells in patients destined to relapse early are present in the initial diagnostic field of blasts. Late relapse may be due to the acquisition of further somatic and/or epigenetic changes. Moreover, it has been shown by analyzing microsatellite markers that some very late relapses of TEL/AML1-positive leukemia most likely represent a new event that occurs in a quiescent precursor leukemia cell harboring an otherwise silent fusion gene that has escaped eradication during initial therapy. 30, 31 Studying the biology of these diseases, both at diagnosis, in minimal residual disease states after selection by chemotherapy, and at relapse, would ideally improve an understanding of how to use current therapy as well as identify new targets. To date, several drug combinations have achieved substantial complete response 2 (CR2) rates varying from 68 to 94% depending on the timing of relapse; however, patients who fail to enter CR2 are not likely to be salvaged with a different combination, suggesting intrinsic drug resistance and a defect in terminal cell Survival after relapse from childhood ALL K Nguyen et al death pathways. Moreover, re-induction rates for patients with multiply relapsed ALL cluster around 40%, suggesting that we have yet to truly understand and circumvent the mechanisms by which resistant lymphoblasts escape cytotoxicity. [8] [9] [10] [11] 32, 33 For newly diagnosed ALL patients, the challenge that remains is to accurately identify patients who will benefit the most from intensive primary therapy. However, this analysis demonstrates that survival for patients with relapsed ALL using conventional therapy remains woefully inadequate, particularly for those who relapse within 36 months of initial diagnosis.
As a result of these and other analyses, recent efforts in the Children's Oncology Group have focused on offering uniform clinical trials for patients with relapsed ALL while gathering important biologic data, thus taking the first steps toward defining whether agents not typically used in the treatment of ALL at initial diagnosis can improve outcome for relapse. The extremely poor survival after relapse underscores the need to focus on improving the outcome of primary therapy for these patients who are unlikely to be salvaged if they relapse. Promising new therapies should be rapidly integrated into trials for subsets of higher risk patients at initial diagnosis.
